Abstract: A method of producing antibodies comprising the step of encoding a peptide sequence from a Domain I perlecan splice variant, wherein the peptide sequence is used to produce anti-peptide antibodies.

Abstract: A method of producing antibodies comprising the step of encoding a peptide sequence from a Domain I perlecan splice variant, wherein the peptide sequence is used to produce anti-peptide antibodies.

Abstract: A method of producing antibodies comprising the step of encoding a peptide sequence from a Domain I perlecan splice variant, wherein the peptide sequence is used to produce anti-peptide antibodies.

Abstract: A method of producing antibodies comprising the step of encoding a peptide sequence from a Domain I perlecan splice variant, wherein the peptide sequence is used to produce anti-peptide antibodies.

Abstract: An isolated polynucleotide that is a splice variant of perlecan formed by a partial or complete deletion of a number of exons within domain I of perlecan, the number of exons deleted from domain I numbering less than the number of exons in domain I. An isolated polynucleotide that is a splice variant of perlecan formed by an insertion of nucleotides within domain I of perlecan. A method of detection and/or quantitation of a splice variant of perlecan domain I gene in a sample, the method comprising making complimentary DNA (cDNA) from messenger RNA (mRNA) in the sample, amplifying portions of the cDNA corresponding to the perlecan gene or parts thereof and detecting and quantifying the amplified cDNA in order to detect or quantify the splice variant.